Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma

Background The high mortality rate associated with epithelial ovarian carcinoma (EOC) reflects diagnosis commonly at an advanced stage, but improved early detection is hindered by uncertainty as to the histologic origin and early natural history of this malignancy. Methodology/Principal Findings Here we report combined molecular genetic and morphologic analyses of normal human ovarian tissues and early stage cancers, from both BRCA mutation carriers and the general population, indicating that EOCs frequently arise from dysplastic precursor lesions within epithelial inclusion cysts. In pathologically normal ovaries, molecular evidence of oncogenic stress was observed specifically within epithelial inclusion cysts. To further explore potential very early events in ovarian tumorigenesis, ovarian tissues from women not known to be at high risk for ovarian cancer were subjected to laser catapult microdissection and gene expression profiling. These studies revealed a quasi-neoplastic expression signature in benign ovarian cystic inclusion epithelium compared to surface epithelium, specifically with respect to genes affecting signal transduction, cell cycle control, and mitotic spindle formation. Consistent with this gene expression profile, a significantly higher cell proliferation index (increased cell proliferation and decreased apoptosis) was observed in histopathologically normal ovarian cystic compared to surface epithelium. Furthermore, aneuploidy was frequently identified in normal ovarian cystic epithelium but not in surface epithelium. Conclusions/Significance Together, these data indicate that EOC frequently arises in ovarian cystic inclusions, is preceded by an identifiable dysplastic precursor lesion, and that increased cell proliferation, decreased apoptosis, and aneuploidy are likely to represent very early aberrations in ovarian tumorigenesis.

[1]  K. Mittal Morphologic precursors of ovarian epithelial tumors. , 1993, Obstetrics and gynecology.

[2]  A. Magliocco,et al.  A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors , 2003, Cancer.

[3]  K. Kinzler,et al.  Targeted inactivation of p53 in human cells does not result in aneuploidy. , 2002, Cancer research.

[4]  R. Drapkin,et al.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Dubeau The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? , 1999, Gynecologic oncology.

[6]  J Gil,et al.  Ovarian dysplasia in prophylactic oophorectomy specimens , 1999, Cancer.

[7]  R. Scully,et al.  Early de novo ovarian carcinoma. A study of fourteen cases , 1994, Cancer.

[8]  A S Whittemore,et al.  Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. , 2000, Journal of the National Cancer Institute.

[9]  C. Lengauer Aneuploidy and genetic instability in cancer. , 2005, Seminars in cancer biology.

[10]  Radisavljevic Sv The pathogenesis of ovarian inclusion cysts and cystomas. , 1977 .

[11]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[12]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[13]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[14]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[15]  P. Kenemans,et al.  Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. , 2004, American journal of obstetrics and gynecology.

[16]  R. Barakat Principles and Practice of Gynecologic Oncology , 2009 .

[17]  R. Scully Pathology of ovarian cancer precursors , 1995, Journal of cellular biochemistry. Supplement.

[18]  J. Boyd,et al.  Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. , 2004, Gynecologic oncology.

[19]  K. Offit,et al.  Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. , 1998, Cancer research.

[20]  S. Sen,et al.  Aneuploidy and cancer , 2000, Current opinion in oncology.

[21]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[22]  Kathleen R. Cho,et al.  Surface Epithelial Tumors of the Ovary , 2011 .

[23]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[24]  B. Werness,et al.  Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. , 1999, Human pathology.

[25]  T. Davis,et al.  Pcp1p, an Spc110p-related calmodulin target at the centrosome of the fission yeast Schizosaccharomyces pombe. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[26]  E. Salmon,et al.  E-MAP-115 (ensconsin) associates dynamically with microtubules in vivo and is not a physiological modulator of microtubule dynamics. , 1999, Journal of cell science.

[27]  J. Boyd,et al.  Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer , 2002, Current opinion in obstetrics & gynecology.

[28]  T. Flotte,et al.  Prognostic significance of DNA content in epithelial ovarian cancer. , 1994, Gynecologic oncology.

[29]  T. Hunter,et al.  PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone , 2002, The Journal of cell biology.

[30]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[31]  Duane A. Compton,et al.  Proliferation of aneuploid human cells is limited by a p53-dependent mechanism , 2010, The Journal of cell biology.

[32]  T. Kreis,et al.  Identification and molecular characterization of E-MAP-115, a novel microtubule-associated protein predominantly expressed in epithelial cells , 1993, The Journal of cell biology.

[33]  J Gil,et al.  Characterization of ovarian dysplasia by interactive morphometry , 1989, Cancer.

[34]  Martin A. Nowak,et al.  The significance of unstable chromosomes in colorectal cancer , 2003, Nature Reviews Cancer.

[35]  P. Duesberg,et al.  Multistep Carcinogenesis: A Chain Reaction of Aneuploidizations , 2003, Cell cycle.

[36]  Martin A Nowak,et al.  Can chromosomal instability initiate tumorigenesis? , 2005, Seminars in cancer biology.

[37]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[38]  T. Davis,et al.  Identification of a human centrosomal calmodulin-binding protein that shares homology with pericentrin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[40]  S. Radisavljevic The Pathogenesis of Ovarian Inclusion Cysts and Cystomas , 1977, Obstetrics and gynecology.

[41]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[42]  B. Werness,et al.  p53, c-erbB, and Ki-67 expression in ovaries removed prophylactically from women with a family history of ovarian cancer. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[43]  M. Wells,et al.  p53 protein expression in putative precursor lesions of epithelial ovarian cancer , 1995, Histopathology.

[44]  F. Penault-Llorca,et al.  Prophylactic oophorectomy , 2003, Cancer.

[45]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[46]  V. Livolsi Blaustein's Pathology of the Female Genital Tract, 5th ed , 2002 .

[47]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[48]  S. Cha,et al.  Flow-cytometric analysis of deoxyribonucleic acid content in advanced ovarian carcinoma: its importance in long-term survival. , 1996, American journal of obstetrics and gynecology.

[49]  T. Rollason Blaustein’s Pathology of the Female Genital Tract , 2003, Springer New York.

[50]  Elise C. Kohn,et al.  Proteomics as a Tool for Biomarker Discovery , 2007, Disease markers.